Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.
@article{Napolitano2014OptimalDO, title={Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.}, author={M. Napolitano and Giorgia Saccullo and A. Malato and D. Sprini and W. Ageno and Davide Imberti and D. Mascheroni and E. Bucherini and Pina Gallucci and A. D’Alessio and T. Prantera and P. Spadaro and S. Rotondo and P. di Micco and V. Oriana and Oreste Urbano and F. Recchia and A. Ghirarduzzi and L. Lo Coco and S. Mancuso and A. Casuccio and G. B. Rini and S. Siragusa}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2014}, volume={32 32}, pages={ 3607-12 } }
PURPOSE
We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.
PATIENTS AND METHODS
Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to… CONTINUE READING
Supplemental Clinical Trials
Interventional Clinical Trial
The duration of anticoagulant treatment in cancer patients with Deep Vein Thrombosis (DVT) of
the lower limbs is still uncertain. The present study addresses the possible role of the… Expand
Conditions | Cancer, Deep Vein Thrombosis |
---|---|
Intervention | Drug |
Figures, Tables, and Topics from this paper
62 Citations
Should anticoagulation therapy be withheld in patients with active cancer after 6 months of low-molecular weight heparin?
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2015
- 1
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2018
- 442
- PDF
Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: a Long-Term Follow-Up
- Medicine
- Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
- 2020
- 1
Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer
- Medicine
- Journal of Thrombosis and Thrombolysis
- 2018
- 3
D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis
- Medicine
- British Journal of Cancer
- 2018
- 14
- PDF
Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.
- Medicine
- Thrombosis research
- 2017
- 47
The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment
- Medicine
- 2020
The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis.
- Medicine
- Thrombosis and haemostasis
- 2020
- 2
References
SHOWING 1-10 OF 29 REFERENCES
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: The extended DACUS study
- Medicine
- American journal of hematology
- 2011
- 41
- PDF
Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study.
- Medicine
- Blood
- 2008
- 120
- PDF
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
- Medicine
- The New England journal of medicine
- 2003
- 1,866
- PDF
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.
- Medicine
- The American journal of medicine
- 2006
- 520
- Highly Influential
The effect of low molecular weight heparin on survival in patients with advanced malignancy.
- Medicine, Biology
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2005
- 555
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
- Medicine
- Archives of internal medicine
- 2002
- 374
- PDF
Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism
- Medicine
- Annals of Internal Medicine
- 2002
- 487
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2004
- 618
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
- Medicine
- The New England journal of medicine
- 2001
- 514
- PDF
D-dimer testing to determine the duration of anticoagulation therapy.
- Medicine, Biology
- The New England journal of medicine
- 2006
- 432